Drug intelligence / Profile preview

KB

Development stage: Unknown
Lead developer: Kiromic BioPharma
Modality: Cell Therapies
Administration: Intravenous

Overview

"KB" is a non-specific term in the provided context, referring to various concepts such as Knowledge Brokering, Kidney Biopsy, Khushi Baby (a mobile health solution), Klein Buendel, Inc. (a company), and Kangaroo Care. However, in the context of drug development, "KB" is also used as a prefix for "KB-GDT-01", an allogeneic gamma delta T-cell product. KB-GDT-01 is a cell therapy designed to leverage the immune system to target cancer cells, currently being investigated in combination with radiotherapy for locally advanced or metastatic non-small cell lung cancer and solid tumors with bone metastases.

Beyond the preview

Go deeper on KB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KB.

Explore the full profile